Compare VICI & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VICI | KVUE |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Specialty Chemicals |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 33.1B |
| IPO Year | N/A | 2023 |
| Metric | VICI | KVUE |
|---|---|---|
| Price | $28.16 | $17.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $34.67 | $20.00 |
| AVG Volume (30 Days) | 13.6M | ★ 32.7M |
| Earning Date | 02-19-2026 | 02-05-2026 |
| Dividend Yield | ★ 6.40% | 4.81% |
| EPS Growth | N/A | ★ 35.31 |
| EPS | ★ 2.63 | 0.75 |
| Revenue | $3,969,078,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $2.85 | $2.81 |
| P/E Ratio | ★ $10.69 | $23.07 |
| Revenue Growth | ★ 4.31 | N/A |
| 52 Week Low | $27.56 | $14.02 |
| 52 Week High | $34.03 | $25.17 |
| Indicator | VICI | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 44.22 | 58.82 |
| Support Level | $27.56 | $16.93 |
| Resistance Level | $28.40 | $17.31 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 47.62 | 67.26 |
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment and leisure destinations, subject to long-term triple net leases. It own nearly 93 experiential assets across a geographically portfolio consisting of nearly 54 gaming properties and nearly 39 other experiential properties across the United States and Canada, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.